ill ion ▁treat ments ▁had ▁been ▁delivered , ▁and ▁ 1 8 ▁of ▁ 7 3 ▁countries ▁in ▁which ▁the ▁disease ▁is ▁considered ▁en demic ▁had ▁progress ed ▁to ▁the ▁surve ill ance ▁stage . ▁ ▁In ▁ 2 0 0 9 , ▁the ▁company ▁said ▁it ▁would ▁cut ▁drug ▁prices ▁by ▁ 2 5 ▁percent ▁in ▁ 5 0 ▁of ▁the ▁poor est ▁nations , ▁release ▁intellectual ▁property ▁rights ▁for ▁subst ances ▁and ▁processes ▁relevant ▁to ▁neglect ed ▁disease ▁into ▁a ▁pat ent ▁pool ▁to ▁encou rage ▁new ▁drug ▁development , ▁and ▁invest ▁ 2 0 ▁percent ▁of ▁prof its ▁from ▁the ▁least - develop ed ▁countries ▁in ▁medical ▁infrastr ucture ▁for ▁those ▁countries . ▁Mé dec ins ▁Sans ▁Front ières ▁wel com ed ▁the ▁decision , ▁but ▁critic ized ▁G SK ▁for ▁failing ▁to ▁include ▁H IV ▁pat ents ▁in ▁its ▁pat ent ▁pool ▁and ▁for ▁not ▁including ▁middle - in come ▁countries ▁in ▁the ▁initi ative . ▁ ▁In ▁ 2 0 1 3 , ▁G SK ▁lic ensed ▁its ▁H IV ▁port folio ▁to ▁the ▁Medic ines ▁Pat ent ▁Pool ▁for ▁use ▁in ▁children , ▁and ▁agreed ▁to ▁negoti ate ▁a ▁license ▁for ▁dol ut eg ra vir , ▁an ▁integr ase ▁in hib itor ▁then ▁in ▁clin ical ▁development . ▁In ▁ 2 0 1 4 , ▁this ▁license ▁was ▁extended ▁to ▁include ▁dol ut eg ra vir ▁and ▁adult s ▁with ▁H IV . ▁The ▁lic enses ▁include ▁countries ▁in ▁which ▁ 9 3 ▁percent ▁of ▁adult